Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Update

Jaguar Animal Health, Inc. (NASDAQ:JAGX – Get Free Report) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totaling 67,479 shares, a decrease of 37.3% from the April 30th total of 107,543 shares. Approximately 18.5% of the company’s shares are short sold. Based on an average trading volume of 156,723 shares, the short-interest ratio is presently 0.4 days.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Tuesday, April 21st. Wall Street Zen raised shares of Jaguar Animal Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Get Jaguar Animal Health alerts:

Check Out Our Latest Stock Report on JAGX

Jaguar Animal Health Stock Performance

Shares of NASDAQ:JAGX opened at $3.22 on Wednesday. Jaguar Animal Health has a one year low of $2.53 and a one year high of $152.25. The company has a debt-to-equity ratio of 4.08, a quick ratio of 0.30 and a current ratio of 0.50. The firm has a market cap of $1.93 million, a PE ratio of -0.01 and a beta of -0.09. The firm’s 50 day simple moving average is $9.18 and its 200-day simple moving average is $24.46.

Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) last posted its quarterly earnings results on Wednesday, May 20th. The biotechnology company reported ($13.60) EPS for the quarter, beating the consensus estimate of ($149.10) by $135.50. Jaguar Animal Health had a negative net margin of 169.04% and a negative return on equity of 1,194.94%. The business had revenue of $20.27 million during the quarter, compared to analyst estimates of $4.21 million.

About Jaguar Animal Health

(Get Free Report)

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.

Featured Stories

• Five stocks we like better than Jaguar Animal Health
• Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
• FirstCash Turns Pawn Into a Growth Machine
• HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
• Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks

Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.